National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Abemaciclib (Verzenios®) HTA ID: 20033

Abemaciclib is indicated for the treatment of women with hormone receptor positive , human epidermal growth factor receptor 2 negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.

 

NCPE Assessment Process Complete
Rapid review commissioned 06/07/2020
Rapid review completed 27/08/2020
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of abemaciclib (Verzenios®) compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.